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Abstract
Title: The Role of Type 2 Diabetes and Metformin Use in Cognitive Decline
Author: Kelley R. Chilson, M.S.
Major Advisor: Frank Webbe, Ph.D.
Objectives: Primary objectives of the present study include exploring the role of
both A1C values and the anti-diabetic medication, metformin, on cognitive decline
through measured by a brief neuropsychological exam (BNE) and the Montreal
Cognitive Assessment (MoCA).
Method: Eleven years of archival cognitive testing and medical information from a
total of 479 East Central Florida Memory Disorder Clinic patients (52.8 % female,
88.5% Caucasian, Mage = 78.79 years) was utilized for the present study.
Participants were placed into two groups: Type 2 diabetes (n = 239) and a control
group (n = 240). Cognitive testing data were collected via MoCA screening tests
and BNE’s that assessed six cognitive domains: language, attention, executive
functioning, motor and processing speed, visuospatial skills, and learning and
memory. Patients diagnosed with Type 2 diabetes were identified from patient
electronic medical records (EMR) searched via Health First Information
Technology (IT).
Results: There was no significant difference in total BNE scores between the Type
2 diabetes group (M = 12.22, SD = 3.83) and the control group (M = 11.80, SD =
3.98; t (477) = 1.17, p = .24, two-tailed). However, a slight difference in domain
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scores was detected between groups as revealed by a one-way between-groups
multivariate analysis of variance (MANOVA), Wilks’ l = .97; F (6, 468) = 2.45, p
= .024; partial eta squared = .03, with a significant difference for visuospatial
domain, F (1, 473) = 5.49, p = .02, partial eta squared = .01. With regard to
metformin use, a significant difference in the learning and memory domain scores
for participants on metformin (M = 1.90, SD = .81) compared to participants on
other medication classes (M = 1.69, SD = .77; t (237) = -1.95, p = .05 was found,
suggesting participants taking metformin demonstrated slightly better performance
on learning and memory measures. Lastly, a significant difference in MoCA scores
between participants taking the drug metformin (M = 20.26, SD = 4.19) compared
to participants taking drugs from other classes of anti-diabetes medications (M =
18.67, SD = 5.05; t (229) = -2.31, p = .02), suggesting participants taking
metformin performed significantly better on this measure compared to participants
taking other anti-diabetes medications.
Conclusions: On cognitive measures of the BNE, participants demonstrated a
higher level of homogeneity than hypothesized, with only slight differences in
cognitive domain scores. The most important findings of the present study were the
differences in cognitive performance between participants taking metformin versus
other anti-diabetic medications. Results support previous literature suggesting a
neuroprotective effect of metformin, as opposed to newer studies that suggest a
cognitive-impairing role of metformin.
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Introduction
Diabetes is a leading cause of death in the United States and the prevalence
of Type 2 diabetes has tripled in the previous four decades (Center for Disease
Control and Prevention [CDC], 2011). A vast line of previous research
demonstrated that individuals diagnosed with Type 2 diabetes display accelerated
levels of cognitive decline compared to individuals without the disease across
various cognitive domains (Awad, Gagnon, & Messier, 2004; McCrimmon, Ryan,
& Frier, 2012; Yeung & Fischer, 2009); however, examining differences in
cognitive decline across varying levels of diabetes self-management as indicated by
A1C values has not been widely explored. A line of research exploring the
relationship between the medication metformin for the treatment of Type 2 diabetes
and its impact on cognitive decline has been developed recently. Results of these
studies yielded inconsistent findings ranging from a neuroprotective role of
metformin against particular brain changes in rat samples (Asadbegi, Yaghmaei,
Salehi, Ebrahim-Habibi, & Komaki, 2016; Chung et al., 2014) and human subjects
(Hsu, Wahlqvist, Lee, & Tsai, 2010; Herath, Cherbuin, Eramudugolla, & Anstey,
2016) to an association between metformin and an increased risk of the
development of various neurodegenerative diseases in human subjects (Chen et al.,
2008; Imfeld, Bodmer, Jick, & Meier, 2012; Yung-Cheng et al., 2014).
Discrepancies identified in this line of research warrant further exploration that will
be provided by the current study.
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The overall aims of this research study were twofold. First, this study seeks
to examine the role of Type 2 diabetes self- management (as measured by A1C
values) on levels of domain-specific cognitive decline in older adults. The second
aim is to determine whether or not older adults taking the medication metformin to
manage Type 2 diabetes experience differences in cognitive decline compared to
those not taking the medication. The aforementioned aims were studied through
utilizing eleven years of archival neuropsychological testing data of 479 older
adults. The following topics will be reviewed:
•

The etiology and epidemiology of Type 2 diabetes

•

The role of hemoglobin A1C and its use as an indicator of Type 2 diabetes
self-management

•

Previous literature examining the relationship between Type 2 diabetes and
cognitive decline

•

Metformin use for the treatment of Type 2 diabetes

•

Previous literature examining the relationship between metformin use and
cognition in older adults.

Results from the present study indicate no significant difference in total BNE
scores between the Type 2 diabetes and control group, with a slight difference in
domain scores. Specifically, statistical analyses revealed a significant difference in
the visuospatial domain, suggesting slightly worse performance on visuospatial
tasks by participants in the Type 2 diabetes group. With regard to metformin use,
two noteworthy findings were found. Firstly, a significant difference in learning
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and memory scores for participants on metformin were found compared to
participants taking other anti-diabetic medications, suggesting better performance
by participants taking metformin. Secondly, an unexpected finding related to the
Montreal Cognitive Assessment (MoCA) was revealed as participants taking
metformin performed better on this multi-domain measure of cognitive functioning
than those taking other anti-diabetic medications.

Review of Literature
Type 2 Diabetes
Epidemiology
Diabetes is estimated to be the 7th leading cause of death in the United
States (CDC, 2017). Type 2 diabetes accounts for approximately 90- 95% of all
diagnosed cases of diabetes, with Type 1 diabetes accounting for the remaining 5%
(CDC, 2017). Approximately 30 million people in the United States (9.4% of the
entire population) have been diagnosed with diabetes and it is estimated 25% of
those with diabetes are unaware they have the disease. Furthermore, approximately
86 million adults in the United States suffer from a condition termed prediabetes, a
health condition that increases a person’s risk of developing Type 2 diabetes, but
has not met the threshold to warrant a full diagnosis. Approximately 90% of this
group is unaware they have the condition (CDC, 2017). An estimated 366 million
individuals are predicted to develop the disease worldwide by 2030, which is
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significantly increased from 171 million in 2000 (Wild, Roglic, Green, Sicree, &
King, 2004).
The prevalence of Type 2 diabetes is highest among American
Indians/Alaskan natives (14.9%), non-Hispanic blacks (12.7%) and Hispanics
(12.1%) (CDC, 2017). Among the Hispanic population, the highest prevalence
occurred in Mexicans (13.8%), followed by Puerto Ricans (12.0%), Cubans (9.0%),
and Central/South Americans (8.5%). Diabetes affects men slightly more than
women (15.3 vs. 14.9 million). It has been found that education significantly
related to the prevalence of diabetes in the United States. Specifically, 12.6% of
adults with less than a high school education has been diagnosed with diabetes
compared to 9.5% of those with a high school education and 7.2% of those with
education beyond high school (CDC, 2017).
Etiology
Diabetes is defined as a group of diseases characterized by high levels of
glucose in the blood (i.e. hyperglycemia) as a result of the malfunctioning action of
insulin (CDC, 2016). Insulin is a hormone produced by the beta cells of the
pancreas that facilitates the proper use and storage of glucose obtained from
carbohydrates during the process of digestion (American Diabetes Association
[ADA], 2015). As digestion occurs, the beta cells of the pancreas secrete insulin to
aid in transferring glucose from the blood into the muscle, fat, and liver cells,
making it available to use for energy. As glucose enters the cells, the amount of
insulin released by the beta cells of the pancreas decreases. For long-term energy
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use, excess glucose that is not transferred to muscle cells is stored in the liver as
glycogen. Lower insulin levels communicate to the liver that glycogen should be
released to sustain energy levels throughout the day (National Institute of Diabetes
and Digestive and Kidney Diseases [NIDDK], 2009).
Type 2 diabetes occurs when the human body cells are unable to use insulin
properly. Specifically, a complication termed insulin resistance develops, which is
characterized by cells’ inability to respond to insulin; therefore, causing
hyperglycemia (CDC, 2016). Insulin resistance furthermore leads to an excess of
insulin levels in the blood as an attempt to compensate for high blood glucose
levels. As this pattern reoccurs over time, the pancreas is unable to produce enough
insulin to address the chronic high glucose levels. High levels of both glucose and
insulin in the blood has been found to be damaging to the human body in a variety
of ways including nerve and blood vessel damage, leading to heart disease, stroke,
kidney failure, blindness and neuropathy (NIDDK, 2009).
Risk Factors
Multiple risk factors that contribute to the development of Type 2 diabetes
have been identified. It has been found that a family history of Type 2 diabetes
serves as a significant predictor of the development of the disease, and the
relationships is stronger relationship for Type 2 diabetes compared to Type 1
(Meigs, Cupples & Wilson, 2000; Van ’t Riet et al., 2010; Scott et al., 2013). Being
overweight, being over 45 years old, not engaging in physical activity at least three
times a week, and ever having gestational diabetes or giving birth to a baby who
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weighed more than nine pounds are considered to be prominent risk factors.
Additional risk factors include belonging to the racial categories of African
American, Alaskan Native, American Indian, Asian American, Hispanic/Latino,
Native Hawaiian or Pacific Islander (NIDDK, 2016).
Many of the most prominent risk factors for the development of Type 2
diabetes are part of a group of conditions known broadly as metabolic syndrome.
Metabolic syndrome is defined as a constellation of conditions that increase the risk
of developing an array of disorders including heart disease, stroke and diabetes.
Conditions that characterize metabolic syndrome include hypertension,
hyperglycemia, excess body fat accumulation around the waist and hip area, and
elevated triglyceride levels in the blood. A relationship between metabolic
syndrome and inactivity, obesity and insulin resistance has been established.
Furthermore, as metabolic syndrome persists without proper management such as
medication implementation and lifestyle changes, the risk of the development of
diabetes increases due to poor management of the factors contributing to insulin
resistance. Importantly, one’s risk of developing Type 2 diabetes is not increased
solely by a diagnosis of metabolic syndrome, but is increased as the individual
conditions that comprise metabolic syndrome become present (ADA, 2014).
Complications
Type 2 diabetes is related to multiple, debilitating health complications.
These complications include heart disease, cerebrovascular disease, strokes, high
blood pressure, neuropathy, kidney damage, eye damage and blindness, skin
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conditions, dental disease and limb amputation. Furthermore, diabetes has been
found to be the leading cause of lower-limb amputations, kidney failure and adult
onset blindness (CDC, 2017). Unfortunately, treatment of diabetes is highly
expensive. The total direct and indirect cost of diabetes in the United States in 2012
was $245 billion. Furthermore, the average annual expenditures for diabetic
individuals is estimated to be approximately $13,7000 (ADA, 2013).
Hemoglobin A1C Values: An indication of Type 2 Diabetes Self-Management
Management of Type 2 diabetes involves adherence to an established set of
guidelines for the purpose of controlling the symptoms related to the diagnosis. A
primary goal related to Type 2 diabetes management is increasing longevity, as
well as encouraging a better quality of life despite the presence of various adverse
symptoms that often make daily life activities difficult. Furthermore, accurate
measurements of one’s ability to manage his or her success in diabetes
management is important. A primary means of accurate diabetes management
measurement is discussed in this section.
Hemoglobin is a protein found in red blood cells that functions to carry
oxygen from the lungs to all cells in the human body. As glucose enters the blood
stream and red blood cells, a subtype of hemoglobin (i.e., A1C) links to the glucose
through a process called glycation. As blood glucose levels rise, the more the
hemoglobin A1C becomes glycated and the number of hemoglobin A1C molecules
that attach to a molecule of glucose is directly proportional to level of glucose in
the blood (NIDDK, 2009).
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The hemoglobin A1C test is a blood test utilized to help diagnose Type 2
diabetes through providing information regarding an individual’s average blood
glucose level over the past three months (NIDDK, 2009). The test specifically
allows for measuring the percentage of hemoglobin A1C molecules that have
glucose attached (ADA, 2013). The American Diabetes Association Standards of
Care identifies a hemoglobin A1C value of 5.7% and less as normal, 5.7-6.4% as
prediabetes and 6.5% or higher as diabetes (ADA, 2014). Although the ability of
the hemoglobin A1C to monitor average blood glucose over time is considered to
be a strength of the test, its inability to detect fluctuations of very low and high
blood glucose levels is considered a notable weakness (Ryan, Duinkerken &
Rosano, 2016).
Hemoglobin A1C values serve as a measure of diabetes self-management
and its value can be altered by a variety of lifestyle behavior changes and
medication (Kitabchi, 2005). The ADA recommends a reduction in time spent
being sedentary, increased moderate physical exercise, weight management, a
balanced and nutrient-dense diet, and taking prescribed medications properly as
part of proper diabetes management program (ADA, 2017). Research demonstrates
incorporation of the aforementioned lifestyle behaviors result in decreased A1C
values in conjunction with improvement to various Type 2 diabetes precursors
including being overweight and an increase in beta cell function and insulin
sensitivity (Kitabchi, 2005; Sjöström et al., 2004). Furthermore, weight loss in
diabetic patients has been found to reduce significantly the associated symptoms of
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high LDL cholesterol and triglyceride levels when compared with a control group
after two and 10 years (Sjöström et al., 2004)). Diabetes self-management has also
been found to be highly effective in individuals with prediabetes. Individuals
diagnosed with prediabetes who adhered to recommended lifestyle changes
decreased their risk of developing type 2 diabetes by approximately 58% (CDC,
2017).
Cognitive Decline
Epidemiology
Dementia is a progressive neurodegenerative disease that negatively
impacts multiple cognitive domains including language, attention and
concentration, executive functioning, motor and processing speed, visuospatial
skills and learning and memory abilities. Furthermore, dementia often affects an
individual’s personality and behavior. Alzheimer’s disease is the most common
form of dementia and accounts for approximately 60-80 % of all cases of dementia
(Alzheimer’s Association, 2017). Additionally, it is the 6th leading cause of death in
the United States and an estimated 5.7 million individuals are living with the
disease at the current time in the United States. Other less commonly diagnosed
forms of dementia include vascular dementia, dementia with Lewy bodies (DLB),
mixed dementia and fronto-temporal lobar degeneration (FTLD) (Alzheimer’s
Association, 2017).
Vascular dementia is the second most commonly diagnosed form of
dementia and accounts for approximately 10% of all cases. Importantly, vascular
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dementia commonly presents as part of a diagnosis of mixed dementia and occurs
in this manner more often than in isolation. Vascular dementia is characterized
predominately by initial deficits in executive functioning (i.e., planning,
organizing, and decision making) in comparison with Alzheimer’s disease, which is
characterized by significant deficits in memory and learning (Alzheimer’s
Association, 2017).
Mild Cognitive Impairment (MCI) is defined as a condition in which an
individual displays mild, but measurable decline in cognitive function that have not
met the diagnostic criteria of dementia. Individuals diagnosed with MCI often
demonstrate cognitive changes that are noticeable to family and friends, but do not
interfere with their ability to carry out normal, daily activities. It has been found
that approximately 30-40% of individuals diagnosed with MCI develop
Alzheimer’s disease within five years (Mattsson et al., 2009; Visser et al., 2009)
however, not all individuals diagnosed with MCI will later develop a form of
dementia. In some cases, MCI has been found to return to a state of normal
cognitive functioning or remain stable over time, demonstrating that MCI need not
be a pre-dementia condition. MCI can be subdivided into two categories: nonamnestic and amnestic MCI. Non-amnestic MCI is characterized by impairments in
cognitive domains other than memory, while amnestic MCI is predominately
characterized by impairment in the domain of memory and learning. The two
subtypes are further divided into single and multidomain depending on the number
of cognitive domains affected (Csukly et al., 2016).
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Type 2 Diabetes and Cognitive Decline
A vast line of research demonstrates both Type 1 and Type 2 diabetes are
associated with an increased risk of cognitive decline in older adults. (McCrimmon,
Ryan, & Frier, 2012; Hassling et al., 2004). The National Institutes of Health (NIH)
Diabetes Mellitus Interagency Coordinating Committee identified in 2010 that
cognition is one of the primary priorities for diabetes research at the present time
and in the following decade (National Institute of Health, 2011). A notable
challenge related to exploring the relationship between Type 2 diabetes and
cognitive decline is determining whether the cognitive changes related to Type 2
diabetes occur independently as a part of diabetes that begins at the onset of the
diagnosis, or as a result of comorbid diseases and old age. Not only has an
association been established between a diagnosis of diabetes and changes in
cognition of older adults, a vast line of research also demonstrates observable brain
abnormalities detected via brain imaging compared to individuals without diabetes
(Yau et al., 2010; Hsu et al., 2012; Falvey et al., 2013; McCrimmon, Ryan, & Frier,
2012; Brundel, Kappelle and Biessels 2014).
Studies exploring the relationships between Type 2 diabetes and cognitive
decline have found deficits in multiple cognitive domains in individuals with
diabetes that are not present in healthy controls. Yeung, Fischer and Roger (2009)
found that individuals with mild Type 2 diabetes performed significantly worse on
measures of executive functioning and semantic speed than healthy controls.
Specifically, significant group differences in both domains were detected in tasks
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that commonly relied on speed, inhibition, and cognitive set shifting. Individuals
with diabetes scored approximately 12% lower on inhibition tasks and 14% lower
on shifting tasks than healthy controls. Importantly, these finding were present in
varying age groups (i.e., young-old, age 53-70 years and old-old, age 71-90 years)
in the sample, demonstrating that the findings are not likely to be a result of
increasing age. Similarly, a key meta-analysis with the aim of comparing effect
sizes for cognitive decline in adults with Type 2 diabetes compared to healthy
controls found that the largest effect sizes were in the domains of motor function
and information processing, while the smallest was found in the domain of
attention and concentration (Palta, Schneider, Biessels, Touradji & Hill-Briggs,
2014). The researchers warned, however, that the relationship between decreased
motor function in the Type 2 diabetes group should be interpreted with caution as it
may be at least partially related to neuropathy.
In addition to the previous findings that reported cognitive decline in
particular domains, evidence also exists that Type 2 diabetes is related to the
diagnoses of MCI, vascular dementia and Alzheimer’s disease. A longitudinal
study conducted by Roberts et al. (2014) utilized a sample of older adults with and
without a diagnosis of Type 2 Diabetes. It was found that Type 2 diabetes was
associated with an increased risk of amnestic MCI, multidomain amnestic MCI,
and multidomain non-amnestic MCI. It was found that each of these relationships
were stronger in men than women, with the risk of multidomain non-amnestic MCI
twice as strong in men than in women. Moreover, a significant relationship was
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also found between single domain non-amnestic MCI in women only. Furthermore,
diabetes severity as measured by during of the disease, presence of complications,
type of treatment and glycemic control, was positively related to a greater risk of
MCI.
It has been found additionally that Type 2 diabetes and prediabetes increase
the risk of progression from non- amnestic and amnestic MCI to Alzheimer’s
disease (Cooper et al., 2015). Multiple studies have demonstrated a relationship
between Type 2 diabetes and Alzheimer’s disease through meta-analyses and
longitudinal studies. Studies have consistently found that the development of both
Type 1 and Type 2 diabetes is related to an increased risk of developing
Alzheimer’s disease (Cheng, Nobel, Tang, Schupf, Mayeux, & Luchsinger, 2011;
Wang et al., 2012; Crane et al., 2013), especially in women (Wang et al., 2012).
Specifically, it has been found that a diagnosis of Type 2 diabetes increases the risk
of developing Alzheimer’s disease as much as 50 to 100% (Wang et al., 2013;
Biessels, Staekenborg, Brunner, Brayne, & Scheltens, 2006).
A significant relationship has also been established between vascular
dementia and a diagnosis of Type 2 diabetes. It has been found that a diagnosis of
Type 2 diabetes increases the risk of developing vascular dementia by
approximately 100 to 150% (Biessels, Staekenborg, Brunner, Brayne, & Scheltens,
2006; Ahtiluoto et al., 2010). Furthermore, the relationship between vascular
dementia and diabetes is particularly strong among individuals aged 75 years and
older (Xu, Qiu, Wahlin, Winblad, & Fratiglioni, 2004).
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Studies have also yielded findings that suggest the occurrence of cognitive
decline in individuals that do not yet meet diagnostic criteria for Type 2 diabetes
(Van den Berg et al., 2008; Hassenstab, Sweat, Bruehl and Convit, 2010; Yates,
Sweat, Yau, Turchiano & Convit, 2012). A study conducted by Van den Berg et al.
(2008) compared participants diagnosed with Type 2 diabetes, metabolic syndrome,
and a control group on cognitive functioning. It was found participants diagnosed
with both Type 2 diabetes and metabolic syndrome performed significantly worse
on measures of information processing speed compared to healthy controls. It was
also revealed that individuals with only Type 2 diabetes demonstrated significantly
worse performance than healthy controls on measures of executive functioning and
attention. Overall, however, the cognitive profiles of individuals in the Type 2
diabetes and metabolic syndrome group did not differ significantly from one
another. The absence of significant differences in information processing speed
between individuals in the Type 2 diabetes and metabolic syndrome group in
combination with similar cognitive profiles of individuals in the Type 2 diabetes
and metabolic syndrome group yields important information about the association
between diabetes and cognitive decline. Specifically, it provides evidence that
cognitive decline in particular domains occurs before an individual meets
diagnostic criteria for Type 2 diabetes. Furthermore, a study conducted by
Hassenstab, Sweat, Bruehl and Convit (2010) found participants diagnosed with
metabolic syndrome performed significantly worse on measures of learning and
recall in comparison to control groups. The researchers additionally discovered that
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of all the conditions that comprise metabolic syndrome, only insulin resistance was
found to be a significant predictor of the learning and recall deficits.
A longitudinal study conducted by Sanz, Hanaire, Vellas, Sinclair and
Andrieu (2012) yielded findings that extend beyond the aforementioned studies by
demonstrating the cognitive changes related to a diagnosis of diabetes in older
adults exacerbates functional impairment in those diagnosed with Alzheimer’s
disease. Functional impairment was measured using the Activities of Daily Living
(ADL) scale over a four-year period. Specifically, diabetes was found not only to
be related to an increase in functional impairment at baseline measurements, but
also shown to be associated with an increased progression of functional impairment
in patients with a recent diagnosis of Alzheimer’s disease (i.e., within 12 months).
As expected, it was found additionally that patients with a diagnosis of Alzheimer’s
disease for longer than one year demonstrated more severe dementia than those
diagnosed within one year.
Pathophysiology of Cognitive Decline and Diabetes Relationship
The exact etiology that accounts for the relationship between diabetes and
cognitive decline remains unclear at the present time, however various factors
related to the adverse impacts diabetes has on the brain are widely considered to
play a prominent role. One of these factors is cerebrovascular disease
(McCrimmon, Ryan, & Frier). As discussed previously, glucose serves as a primary
source of energy for all cells in the human body, including neurons. The brain
consists of approximately 100 billion neurons, making it the most energy
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demanding organ in the human body. The brain’s ability to perform cognitive
functions properly across all domains relies on glucose as a source of fuel.
Plausibly, the dysregulation of glucose levels that characterizes diabetes is likely to
have a significant impact on the brain’s ability to operate properly.
The literature demonstrates several primary, however not independent, areas
of change that underlie the relationship between cognitive dysfunction and Type 2
diabetes. These areas include molecular, micro (i.e., white matter and vascular) and
macro-structural changes, as well as brain volumetric changes. Each of these
changes will be reviewed in the following section.
The risk factors that accompany and contribute to Type 2 diabetes including
hyperglycemia, hypertension and elevated triglyceride levels have been found to
trigger an overproduction of a reactive oxygen species that in turn, reduces the
availability of a crucial vasodilator, nitric oxide, which initiates vascular
inflammation. Compounding this event is the presence of hyperglycemia, which
increases the body’s cellular response to the vasoconstrictor, endothelin-1. It has
been found this process, in combination with abnormal insulin levels may lead to a
calcium accumulation that tends to result in increased clotting of the blood. These
occurrences in combination with elevated triglycerides increase the risk for
arteriosclerosis, or stiffening of the artery walls (Bertram, Brixius, & Brinkmann,
2016).
Diabetes has not only been found to affect the peripheral nervous system,
but also the central nervous system. An additional molecular factor hypothesized to
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contribute to cognitive decline in those diagnosed with Type 2 diabetes relates to
abnormal insulin levels in the brain. (van der Heide, Ramakers, & Smidt, 2006). It
is thought that insulin increases the action of GLUT4 (a glucose transporter), which
is present in the brain. Because of this, disruption of insulin secretion that is
characteristic of Type 2 diabetes reduces insulin levels in the brain and may affect
this mechanism thus leading to glucose dysregulation (Umegaki et al., 2013).
Insulin receptors in the brain and are particularly localized at synapses in the
hippocampus (Abbott et al., 1999). Insulin has been found to play a role in neuron
survival and death via two different pathways in the brain and studies have found
that insulin has the ability to inhibit neuron death. Research in this area
demonstrates that Type 2 diabetes influences a reduction in insulin and its receptors
in the brain, therefore reducing its ability to inhibit neuron death (van der Heide,
Ramakers, & Smidt, 2006).
Consistent with the aforementioned finding of information processing
deficits in individuals diagnosed with Type 2 diabetes, evidence exists that
microstructural abnormities occur that are related to myelination changes in white
matter. These changes are hypothesized to slow processing speed given the
knowledge of the role of myelination in speed of information conduction.
Furthermore, this finding has been established across various age groups (i.e.,
adolescence, middle adulthood and older adulthood), lending evidence that the
finding is not simply related to the aging process (Yau et al., 2010; Hsu et al., 2012;
Falvey et al., 2013). Furthermore, an innovative study utilizing a 3-Tesla diffusion-
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weighted MRI scan and a detailed cognitive assessment followed by an analysis of
white matter tractology in the entire brain found adults with Type 2 diabetes
showed significantly less brain region white matter connectivity in the unicate
fasciculus, superior longitudinal fasciculus, inferior longitudinal fasciculus and the
splenium of the corpus callosum compared to healthy controls. Furthermore, it was
found that the lack of connectivity in all brain lobes was associated with
information processing speed slowing that was independent of age (Reijmer et al.,
2013).
A meta-analysis conducted by Brundel, Kappelle and Biessels (2014)
demonstrated significant reductions in total brain volume reduction in participants
diagnosed with Type 2 diabetes compared to healthy controls. Across all studies
examined, higher hemoglobin A1C values in combination with high blood pressure
and a longer duration of the diagnosis were the strongest predictors of total brain
volume reduction. Likewise, a study conducted by Brundel, van den Heuvel, de
Bresser, Kappelle and Biessels (2010) found reductions in cerebral cortical
thickness predominately in the right temporal lobe of those diagnosed with Type 2
diabetes in comparison to healthy controls. Specifically, the most atrophy was
detected in the hippocampal region.
Metformin
Metformin, or commercially known as GlucophageÒ, GlumetzaÒ ,
RiometÒ, or FortametÒ is an orally administered medication commonly used to
treat Type 2 diabetes. Metformin is widely considered to be the first-line
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pharmacological treatment for Type 2 diabetes and is a treatment modality that has
been reported to be highly effective, safe, and inexpensive (ADA, 2017).
Metformin is classified as a biguanide, a term categorizing the medication based on
the manner in which it operates. Metformin is the only medication in the class of
biguanides. Metformin operates in multiple ways by decreasing glucose production
and absorption in the small intestine while simultaneously increasing the sensitivity
bodily cells to insulin, without actually stimulating insulin secretion (Rojas &
Gomez, 2013). Secondary benefits of the medication that help to manage
conditions related to Type 2 diabetes include lowering blood cholesterol and
triglyceride levels (Yung-Cheng et al., 2014).
Metformin operates in the liver by reducing glucose output and achieves its
widespread effects through its ability to target the enzyme, adenosine
monophosphate-activated protein kinase (AMPK). Activation of this enzyme
results in glucose uptake and modulation of insulin secretion by the beta cells in the
pancreas among numerous other effects, including inhibition of cholesterol and
triglyceride synthesis. It has also been found that the medication has the ability to
cross the blood-brain barrier, which makes exploring the effects of metformin on
the brain and cognitive functioning of particular interest (Łabuzek et al., 2010).
A large meta-analysis conducted by Palmer et al. (2016) explored the
efficacy and safety of multiple glucose-lowering medications commonly prescribed
for the treatment of Type 2 diabetes. The meta-analysis was conducted by utilizing
data obtained from 301 clinical trials. When comparing hemoglobin A1C values

20
for patients taking metformin versus other medications used to treat Type 2
diabetes (i.e. Sulfonylurea, thiazolidinedione, dipeptidyl peptidase (DPP-4)
inhibitor and α-glucosidase inhibitor), significantly lower hemoglobin A1C levels
were found in patients taking metformin. Furthermore, this finding was established
without evidence of metformin being related to hypoglycemia or weight gain.
Large reductions in A1C values were additionally found for dual therapy (the
addition of other of drug classes to metformin), beyond the reduction achieved by
metformin alone.
Similar to Palmer et al. (2016), a meta-analysis conducted by Bennett et al.
(2011) also sought to summarize the costs and benefits associated with multiple
medications used to treat Type 2 diabetes including metformin, sulfonylureas,
thiazolidinediones, meglitinides, DPP-4 inhibitors, and glucagon-like peptide-1
receptor agonists. It was found the aforementioned medications reduced patient
A1C levels by approximately one percent while metformin was found to be
significantly more effective than DPP-4 inhibitors. Furthermore, metformin
reduced LDL cholesterol at a higher level than other medications while
sulfonylureas were found to have a 4-fold higher risk for mild or moderate
hypoglycemia than metformin alone. Together, these studies lend support to the
ADA’s claim that metformin is an appropriate first-line pharmacological treatment
for Type 2 diabetes.
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Metformin and Cognition
With consideration of the aforementioned benefits of metformin, and the
reviewed literature related to the negative impact of insulin resistance on cognitive
functioning, it is plausible to posit that diabetes management using this metformin
would slow cognitive decline in older adults with diabetes. At the current time,
however, the literature related to this area demonstrates the medication is related to
both improvement and decline in cognition, leaving the relationship between the
two variables unclear.
Various lines of evidence demonstrate metformin has a neuroprotective and
positive impact on cognitive functioning (Hsu, Wahlqvist, Lee, & Tsai, 2010;
Herath, Cherbuin, Eramudugolla, & Anstey, 2016). Studies have shown that taking
metformin for the treatment of diabetes is related to a significant reduction in the
risk for dementia in patients with Type 2 diabetes and this relationship is even
stronger when combined with sulfonylureas (Hsu, Wahlqvist, Lee, & Tsai, 2010).
Specifically, a Taiwanese study conducted by Hsu, Wahlqvist, Lee, and Tsai (2010)
found that together, the two medications decreased the risk of dementia by
approximately 35% over a span of eight years. Furthermore, a more recent large,
longitudinal study conducted by Herath, Cherbuin, Eramudugolla, and Anstey
(2016) examined the effect of various diabetes treatment types on change in
measures of cognitive domains over four years. Patients who took metformin only
demonstrated better cognitive performance in the domains of verbal learning,
working memory, and executive functioning at baseline measurement compared to
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participants in all other treatment types (i.e. insulin, controlled diet, exercise, other
oral medications and metformin in addition to other oral medications). Importantly,
this finding remained significant after adjusting for the effects of physical exercise,
smoking, hypertension and Body Mass Index (BMI). Longitudinally, however, the
only significant difference related to metformin in comparison with the other
groups was found for psychomotor speed. This study appears to be the only one of
its kind that explored the effect of metformin on specific cognitive domains.
The neuroprotective effect of metformin was also found in a study utilizing
a rat sample (Mostafa, Ismail, & Ghareeb, 2016). By implementing an experimental
design, the researchers induced learning and memory deficits in the rat sample via
the utilization of a pharmacological model of cognitive impairment, scopolamine
injection. Scopolamine exerts its effects by inducing dysregulation of cholinergic
and memory pathways in the brain. In this study, scopolamine was administered on
14 consecutive days. Following the final injection of scopolamine, one group of the
rats were treated with metformin at 2 different doses (i.e., 100 mg/day and 300
mg/day). A water maze and a passive avoidance task was used to test the rats’
memory abilities and the composition of various brain chemicals related to memory
loss were also measured (i.e., inflammatory markers, nitric oxide, Akt, and
phospho-tau). It was found that 100 mg of metformin served as a protective
mechanism against learning and memory deficits as measured by both the water
maze and passive avoidance tasks. Moreover, this dose of metformin was also
found to be related to a significant reduction in inflammation and Akt. A decrease
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in Akt is of particular relevance because it serves as a primary regulator of tau
biology by affecting both the tau kinases and tau protein quality (Dickey et al.,
2008) which are closely associated with the development of Alzheimer’s disease.
Rats administered the 300-mg dose of metformin’s performance was not
significantly different from those treated with scopolamine on both the water maze
and passive avoidance tasks.
In contrast, results from multiple studies indicate metformin has a harmful
impact on the brain and cognitive functioning (Chen et al. 2008; Imfeld, Bodmer,
Jick, & Meier, 2012; Yung-Cheng et al., 2014). In a study examining the
relationship between various antidiabetic drugs, including metformin, and the risk
of developing Alzheimer’s disease in a large population- based case-control
analysis, it was found that long-term metformin use (i.e. greater than 60
prescriptions) was related to a higher risk of developing Alzheimer’s disease
(Imfeld, Bodmer, Jick, & Meier, 2012). When comparing the risk of developing
Alzheimer’s disease while taking metformin with other long-term use of
antidiabetic medications (i.e., sulfonylureas and thiazolidinediones) the risk of
developing the disease was not significantly higher for those using sulfonylureas
and thiazolidinediones. Furthermore, a study conducted by Chen et al. (2008). The
researchers aimed to determine whether metformin had an impact on various
cellular processes that contribute to the development of Alzheimer’s disease
including amyloid precursor protein (APP) metabolism and production of the Aβ42
amyloid protein. It is well established that the Aβ42 protein is highly detrimental to
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a neuron’s ability to function properly, and an accumulation of the proteins are
thought to be a beginning factor in the development of Alzheimer’s disease. Results
demonstrated that metformin led to a significant increase in intracellular and
extracellular Aβ42 protein levels. Moreover, the researchers discovered the
relationship between metformin and increased Aβ42 levels appeared to be partially
dependent on the aforementioned AMPK activation that this medication targets.
Changes in brain structure have also been identified in relation to metformin
use (Yung-Cheng et al., 2014). A study conducted by Yung-Chen et al. (2014) that
compared the effect of metformin on brain metabolic activity utilizing FDG
positron emission tomography. They found metformin use was associated with
increased metabolic activity in the white matter located in the right temporal, right
frontal and left occipital lobes in patients taking metformin in comparison to two
other groups (i.e., patients in metformin withdrawal and patients not taking
metformin). In contrast, decreased metabolic activity in the memory system (i.e.,
the hippocampus, left fusiform gyrus and the ventromedial prefrontal cortex) was
found in patients taking metformin. The researchers posited the increase in
metabolic activity in white matter may be a result of metformin-induced
inflammation of the neurons in these areas. Furthermore, the researchers found that
the impact of metformin on white matter may be related to how long it has been
since the patients stopped taking the medication. Specifically, a significant negative
correlation was found between how long it has been since the patients stopped
taking metformin and metabolic activity in white matter. This finding in particular
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provides evidence that the potentially damaging effects of metformin may be
reversible upon discontinuation of the medication.
Statement of Purpose
The present study is novel in that at the current time, few studies have
examined the role of A1C values on levels of domain-specific cognitive decline
(i.e., lower A1C values being related to better cognitive performance while higher
A1C values are related to worse cognitive performance). Instead, studies often
explore the relationship between a diagnosis of Type 2 diabetes and developing a
neurodegenerative disease like Alzheimer’s disease. Furthermore, few studies have
utilized a large battery of neuropsychological tests to examine the relationship
between cognitive decline and diabetes. The more comprehensive approach of the
present study was designed to contribute to resolving some of the mixed patterns of
results across the reviewed studies varying in cognitive domains and measures
utilized.
The reviewed literature also indicated inconsistent results for the
relationship between the use of metformin for the treatment of Type 2 diabetes and
cognitive functioning. Varying results warrant further study in this area. Also
making this relationship an important area of focus for the present study is the wide
use of the medication for the treatment of Type 2 diabetes and the research
demonstrating its safety and utility for the treatment of Type 2 diabetes.
Hypotheses
Based on the reviewed literature, the hypotheses of this study were as follows:
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1. Participants with higher A1C values will have significantly lower BNE
scores (i.e., more domains within the “borderline” or “impaired” range)
as compared to participants with A1C values within the normal range.
2. The medication metformin will impact cognitive performance as
measured by the BNE.
Method
Participants
Archival participant data from the Health First Aging Institute and the East
Central Florida Memory Disorder Clinic (ECFMDC) were utilized for this study.
Participants were selected from patients who had been assessed for cognitive
abnormalities using a brief neuropsychological evaluation (BNE) at the ECFMDC.
Participants consented to the use of their testing data after being informed of the
ECFMDC’s research aspects prior to commencement of their testing session. For
patients who were not competent to consent to the use of their data, consent was
obtained from his or her durable power of attorney. This research has been
approved by the Florida Institute of Technology’s Institutional Review Board.
The sample utilized for this study consisted of 479 male and female
ECFMDC patients who had undergone a full BNE. The sample consisted of 279
females (58.2%) and 200 males. Age of participants ranged from 46 to 95 years (M
= 78.79, SD= 7.74). A large majority of the sample was Caucasian/White (88.5%),
with 2.7% identifying as Hispanic, 8.4% identifying as African American, .8%
identifying as Asian and .6% identifying as Native American. Additionally, .8% of
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participants identified their race as “other”, while .8% provided no response.
Participant years of education ranged from 3 to 24 years (M = 13.45, SD = 2.86).
To establish the Type 2 diabetes group (n = 239), all participants from the
ECFMDC research database were used who were diagnosed with Type 2 diabetes
and had at least one documented A1C measurement in their medical chart.
Participants who were not diagnosed with Type 2 diabetes were selected randomly
from the ECFMDC research database to establish the control group (n = 240). A
random number generator selected 240 numbers from a total of 2,274 patients that
corresponded to the number of patients who did not have a diagnosis of Type 2
diabetes.
Setting
BNE’s were carried out on weekdays between 8:00 a.m. and 5:00 p.m. Each
BNE took place in a small, neutral colored, examination room at the East Central
Florida Memory Clinic in Melbourne, Florida. Within the room was a desk with
two chairs, and a computer and keyboard placed to the far right or left side of the
desk surface. Examination rooms also included a small file cabinet in a corner of
the room. For all tests, the participant and the psychometrist sat facing each other
across a three-foot-wide table. Pencils needed for the examination were placed to
the side of testing materials.
Materials and Measures
Assessment of Diabetes. Participants in the diabetes group were diagnosed
with diabetes based on a physician diagnosis or the use of diabetes medications.
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Furthermore, a determination of a Type 2 diabetes diagnosis was further confirmed
by a history of A1C value measurements in his or her medical record. These factors
serve as a safeguard against participants misreporting the diagnosis.
Neuropsychological Exam. Each participant underwent a brief battery of
neuropsychological assessments that included the Montreal Cognitive Assessment
(MoCA) the Quick Exit, Controlled Oral Word Association Test (COWAT),
MACK SF4, a Supraspan Serial Word List, Symbol Digit Modalities Test
(SDMT), Trailmaking Test (TMT) parts A and B, the Victoria Stroop test (VST), a
Clock Drawing Test (CDT), and the Rey Complex Figure Test. The
neuropsychological measurements were used to assess the domains of attention and
concentration, memory (learning and delayed recall), executive functioning, motor
processing speed and visuo-spatial performance. Furthermore, three tests were
given to assess the presence and severity of psychological difficulties including the
Geriatric Depression Scale (GDS), the General Anxiety Index (GAI) and the Brief
Symptom Inventory (BSI).
Montreal Cognitive Assessment (MoCA). The MoCA (Nasreddine et al.,
2005) is a cognitive screening tool designed to assist in the detection of mild
cognitive impairment. The examiner administers a variety of tasks which measures
visuo-spatial, executive functioning, naming, language, memory, attention, delayed
recall, abstraction, and orientation. The MoCA is scored by the examiner for a total
of 30 possible points. A cut off score of 26 is used to suggest less than normal
cognitive functioning, while a score of 26 or greater is classified as normal. Level
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of education is also adjusted by adding one point to a patient’s total score for those
with equivalent to or less than twelve years of education.
Quick EXIT. The Quick Exit (Larson & Heinemann, 2010) is a short, 14item abbreviated version of the original EXIT-25 (Stockholm et al., 2005). The test
was developed to measure executive functioning ability through a variety of tasks
that focus on participants’ levels of perseveration, apathy, intrusions, disinhibition,
utilization and imitation behavior, motor impersistence and concentration. Test
items consist of number-letter sequencing, design fluency, sentence repetition,
thematic perception, memory with a distraction task, interference inhibition, Luria
hand sequence, motor perseveration, counting and serial-order reversal, and
imitation behavior. The Quick EXIT is scored on a scale of 0-28, with higher
scores indicating greater executive functioning deficits. Possible item scores range
from zero to two.
Controlled Oral Word Association Test (COWAT). The COWAT (Benton,
Hamsher & Siven, 1983) is a phonemic and semantic verbal fluency test that
measures the participants’ ability to spontaneously produce words that belong to
particular categories designated by a letter of the alphabet (i.e., C, F and L) or to
particular semantic categories (i.e., animals, fruit and vegetables). Individuals are
allowed one minute to names as many words possible that begin with the
designated letter or that represent the semantic category.
Mack SF4. The Mack SF4 (Mack et al., 1992) is a short form of the 60 item
Boston Naming Test and consists of 15 items that assess visual naming ability by
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utilizing a series of 15 black and white drawing of common objects (e.g., house,
octopus, bench, stethoscope or palette). The examiner presented the various objects,
one at a time, and records the patient’s ability to identify the objects. The test was
discontinued after eight consecutive failures. Phonemic and semantic cues are
provided by the examiner following patients’ difficulty in naming the object.
Reliability of the test is weaker than the full Boston Naming Test, ranging from .49
to .84; however, the validity of the Mack SF4 is strong, ranging from .62 to .98.
Supraspan serial word list. This test was designed by the East Central
Florida Memory Disorder Clinic and measures auditory-verbal learning and
memory. The examiner read a list of 10 single-syllable words over each of five
trials. Following each reading, the participant was asked to immediately recall the
words in the list each time. Without notice, the patient was then prompted to recall
the words from the list after a delay of five to ten minutes. Following the recall, the
examiner records the number of words correctly recalled and any intrusions and/ or
repetitions. The score is determined by percentage of words learned over the trials,
with the best trial score and delay trial recorded. A recognition trial was also
presented to the patient that consists of a list of the 10 previously remembered
words among various distractor words. The number of patient word recognitions,
commissions and omissions are recorded.
Symbol Digit Modalities Test (SDMT). The SDMT (Smith, 1982) is a test
that assesses participants’ divided attention, visual scanning, tracking and motor

31
speed. The participant is allotted 90 seconds to fill in numbers that correspond to
particular symbols according to the way in which they are paired in a key above.
Trailmaking Test (TMT) part A and part B. The TMT (Partington &
Leiter, 1949; Reitan, 1955) is a test comprised of two parts; Part A and Part B. Part
A is designed to measure one’s visual tracking, scanning and sequencing abilities.
The patient was provided with a sheet of paper numbered one through 25 and asked
to connect each number in ascending order. The score is calculated from the time
the patient takes to complete the task. Each error is corrected immediately by the
examiner. Part B of the Trailmaking Test measures one’s set shifting and cognitive
flexibility. The patient was presented with a sheet of paper with both numbers and
letters enclosed in circles and instructed to alternate between a number and letter in
ascending order. The score is calculated as the time the patient takes to complete
the task. The patient was allotted a maximum of five minutes to complete the task.
Victoria Stroop Test (VST). The VST (Regard, 1981) measures selective
attention and cognitive flexibility. The test has 3 components consisting of 23 items
each. The first component (Part D) of the test consists of 24 colored (i.e., blue,
green, red and yellow) dots arranged in rows. The Participant was asked to name
the colors of the dots as quickly as he or she can. The second component (Part W)
is similar to Part D, but the dots are replaced by common words and serves as a
control task. The participant was prompted to name the color of the words while
ignoring the verbal content. In the third and most difficult component of the test
(Part C), the common words are replaced by the names of colors (i.e., blue, green,
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red and yellow) that do not correspond to the printed color (e.g., blue is written in
green ink). The participant was prompted to name the color of the print and not
read the word, which is the automatic response. The errors in naming are corrected
by the examiner each time it occurs and the total errors and the time it took to
complete each part is recorded. Following the task, an interference score is
calculated to determine the amount of extra time needed to name the colors in Part
C.
Clock Drawing Test (CDT). The CDT (Mendez et al., 1992) is a test that
assesses participants’ visual-spatial, constructional and executive abilities through
drawing an analogical clock face on a piece of paper. Following the completion of
the drawing, the patient was asked to set the time to 10 after 11. The participant’s
response is then scored based on his or her ability to correctly draw the contour of
the clock, place the numbers in the correct location and order, and set the clock
hands to the correct time.
Rey Complex Figure Test (ROCF). The ROCF (Rey, 1941; Osterrieth,
1944) is a test that assesses the examinee’s visual-spatial constructional ability and
visual memory. The test is comprised of 3 conditions, all of which relate to the
examinee’s ability to copy and later remember multiple details of a complex figure.
In the first condition, the examinee was provided with an image of the complex
design and is prompted to copy the design on an 8 ½ by 11-inch blank sheet of
paper with a pencil. The examinee was given five minutes to complete the task. In
the second condition, the examiner removed the image of the design, provided a
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clean sheet of paper, and prompted the examinee to reproduce the complex design
from memory within five minutes. After a 30-minute delay period that is filled with
interfering, non-constructional tasks in the testing battery, the examinee is again
prompted to reproduce the design from memory. Condition three is an incidental
learning test, therefore there was no warning there would be a delayed recall
condition. Following the 3 conditions each condition is scored based on accuracy
and quality of the drawings.
Geriatric Depression Scale (GDS). The GDS (Yesavage et al., 1983) is a
30-item self-administered mood assessment scale used to screen the elderly for
depression. The examiner presented the questionnaire to the examinee that consists
of 30 yes/no items that address changes in mood based on how the patient is feeling
at the time. The test takes approximately five to ten minutes to complete. GDS
scores range from zero to thirty. Scores of 0-9 indicate no depression, 10-14
indicate mild depression, 15-19 indicate moderate depression, and 20-30 indicate
severe depression.
Geriatric Anxiety Inventory (GAI). The GAI (Pachana et al., 2007) is a 20item self-administered mood assessment scale used to screen for typical symptoms
of anxiety and is comprised of agree/disagree statements only. The questions are
tailored to fit the common symptoms of anxiety in the elderly with only including a
limited number of somatic symptom-related questions to avoid confusion between
somatic complaints related to anxiety and general medical conditions.
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Brief Symptom Inventory (BAI). The BAI (Derogatis, 1993) is a 53-item
self-report instrument that assesses psychological distress and symptoms of
psychiatric disorders. The patient was prompted to rate their experience with the
symptoms over the past 7 days, including today, on a five-point Likert scale. The
BSI consists of nine primary dimensions (somatization, obsessive-compulsive,
interpersonal sensitivity, depression, anxiety, hostility, paranoid ideation, and
psychoticism). It also includes three global indices of psychological distress
(Global Severity Index, Positive Symptom Distress Index, and Positive Symptom
Total).
Procedure
A trained psychometrist administered and scored the brief
neuropsychological assessment (BNE). An interdisciplinary professional team
consisting of a geriatrician, social worker, neuropsychologist, neurologist, geriatric
psychologist, and clinical psychology doctoral students formed a case review panel
and collaboratively determined the appropriate diagnosis and treatment for each
participant. The results of a complete medical examination, laboratory tests
including MRI, and a psychosocial interview were used in forming an accurate
diagnosis. Each patient was later informed of their diagnosis, given a treatment
plan, and recommended for future neuropsychological assessment depending on the
diagnosis given. A patient’s cognitive performance scores from the brief
neuropsychological battery were separated into appropriate domains and then
labeled with the impairment categories accordingly with “Within Normal Limits”,
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“Borderline”, or “Impaired”. Data from the BNE was later entered into a database
by a trained psychometrist for research purposes at the East Central Florida
Memory Disorder clinic.
The study consisted of an archival investigation that began by the primary
researcher combining patient cognitive testing data from the ECFMDC database
with data retrieved from Health First’s information technology (IT) department.
Data from IT provided information from patients’ medical charts including a
diagnosis of Type 2 diabetes, A1C values and their corresponding dates of
measurement, and patient’s history of anti-diabetic and anti-dementia medications.
A final database pertaining both sources of information combined was used to
conduct statistical analyses.
Statistical Methods
All data were analyzed using SPSS version 25. Descriptive and frequency
summary data were calculated to obtain the demographic information for the
sample used for this study, as well as for characterizing the anti-diabetic drugs in
the Type 2 diabetes group and the cognitive diagnoses across both groups. To test
the role of A1C values on cognitive performance, both a multivariate analysis of
variance (MANOVA) and a Pearson product-moment correlation coefficient were
utilized. The effect of the medication metformin on cognitive performance as
measured by the BNE was explored by a variety of statistical methods including
multiple independent samples t-tests. These were conducted to compare BNE
cognitive domain scores for participants taking metformin with participants taking
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any other class of anti-diabetic medications. Independent samples t-tests were also
used to compare cognitive performance by total BNE score and MoCA scores
between participants taking metformin with participants taking other medication
classes. Finally, as part of post-hoc analyses, 2 areas outside of the originally
proposed hypotheses were explored. Specifically, 1) differences in cognitive
diagnoses across the Type 2 diabetes and control groups were investigated by
conducting a chi square test for independence, and 2) differences in BNE subtest
scores across the Type 2 diabetes and Control group were explored. This was
achieved by comparing group means via conducting independent samples t-tests.
Results
Prior to tests of hypotheses, group make up by gender, age, race and
ethnicity was examined. The control group was comprised of 64.2% females, 95%
Caucasian with 92.1% identifying as Non-Hispanic. Control group patients’ ages
ranged from 48 to 95 years (M=79.63, SD = 7.4) with years of education ranging
from 8 to 21 years (M =13.66, SD = 2.7). The Type 2 diabetes group was
comprised of 52.3% females, 82% Caucasian with 89% identifying as NonHispanic. The Type 2 diabetes group ages ranged from 46 to 95 years (M = 77.94,
SD = 8.0) with years of education ranging from 3 to 24 years (M =13.66, SD = 3.0).
Groups did not differ from one another in level of education as determined with an
independent samples t-test, t (473) = 2.37, p = .12. Groups significantly differed
from one another on age as determined with an independent samples t-test, t (471)
= 2.37, p = .02. Cross tabulated frequencies also indicated a significant difference
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in gender composition across groups, c2 (1, n = 479) = 6.5, p = < .05, phi = .12.
Hypothesis 1
This study hypothesized participants with higher A1C values will have
significantly lower BNE scores (i.e., more domains within the “borderline” or
“impaired” range) than participants with A1C values within the normal range. This
hypothesis was tested with relational and comparative statistics.
The relationship between cognitive performance (as measured by both the
total BNE score and the MoCA score) and A1C scores was investigated using a
Pearson product-moment correlation coefficient. Preliminary analyses were
conducted to ensure no violation of the assumptions of normality, linearity and
homoscedasticity. All correlations were found to be statistically insignificant.
Secondly a one-way between-groups multivariate analysis of variance
(MANOVA) was performed to investigate group differences in BNE domain
scores. Six dependent variables were used: language, attention, executive
functioning, motor and processing speed, visuospatial skills, and learning and
memory scores. The independent variable was group (i.e. Type 2 diabetes or
control). Preliminary assumption testing was conducted to check for normality,
linearity, univariate and multivariate outliers, homogeneity of variances, with no
serious violations noted. There was a statistically significant difference between the
Type 2 diabetes and control group on the combined dependent variables, Wilks’

l = .97; F (6, 468) = 2.45, p = .024; partial eta squared = .03, demonstrating a small
effect size. When results from the dependent variables were considered separately,
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the only one to reach statistical significance was the visuospatial domain, F (1, 473)
= 5.49, p = .02, partial eta squared = .01, demonstrating a small effect size. An
inspection of mean scores indicated that the Type 2 diabetes group obtained
slightly lower visuospatial scores (M = 2.17, SD = .79) than the control group (M =
2.00, SD = .82).
Two independent-samples t-tests were conducted to compare cognitive
performance (as measured by both the total BNE scores and MoCA scores) for the
Type 2 diabetes and control group. There was no significant difference total BNE
scores between the Type 2 diabetes group (M = 12.22, SD = 3.83) and the control
group (M = 11.80, SD = 3.98; t (477) = 1.17, p = .24, two-tailed). The was also no
significant difference in MoCA scores between the Type 2 diabetes group (M =
19.14, SD = 4.90) and the control group (M = 18.86, SD = 4.70; t (467) = -.65, p =
.52, two-tailed).
Hypothesis 2
This study also hypothesized the medication metformin would impact
cognitive performance as measured by the BNE. Participants in the Type 2 diabetes
group in this study were on a variety of classes of anti-diabetic medications
including metformin, sulfonylureas, meglitinides, thiazolidinediones, sodiumglucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide (GLP-1)
agonists and insulin. Out of the 239 participants in the Type 2 diabetes group, 218
participants were taking an anti-diabetic medication. Seventy-three participants
were taking metformin (30.5%), 63 participants were taking a sulfonylurea
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(25.4%), 61 participants were on insulin (25.5%), 12 participants were taking
thiazolidinediones (5%), 7 participants were taking a SGLT-2 inhibitor (2.9%),
while only 1 participant was taking a meglitinide (0.4%) or a GLP-1 agonist
(0.4%). Additionally, 21 participants were not indicated as taking any anti-diabetic
medications (8.9%).
Figure 1. Composition of anti-diabetic medications in Type 2 diabetes group
.4%
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Insulin
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To explore the impact of metformin on cognitive performance,
independent-samples t-tests were conducted to compare BNE cognitive domain
scores for participants taking metformin with participants taking all other classes of
anti-diabetic medications. There was a marginally significant difference in the
learning and memory domain scores for participants on metformin (M = 1.90, SD =
.81) compared to participants on other medication classes (M = 1.69, SD = .77; t
(237) = -1.95, p = .053. This suggests participants taking metformin demonstrated
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slightly better performance on learning and memory measures. All other
comparisons were statistically insignificant. Comparison results are reported below
in Table 1.
Table 1. Results of t tests and descriptive statistics of BNE domain scores by
medication
Metformin Scores

Other Medication Scores

t-test

p-value

M
1.90

SD
.81

M
1.69

SD
.77

-1.95

.05*

Language

2.25

.73

2.13

.77

-.1.19

.24

Attention

2.22

.81

2.05

.85

-1.47

.14

Executive
Functioning

2.07

.83

1.93

.83

1.16

.25

Motor
Processing

2.10

.77

2.08

.85

1.11

.91

Visuospatial

2.15

.80

2.18

.79

.25

.80

Learning and
Memory

Further independent- sample t-tests were conducted to compare cognitive
performance by total BNE score and MoCA scores between participants taking
metformin with participants taking other medication classes. There was no
significant difference in total BNE scores for participants on metformin (M =
12.67, SD = 3.57) compared to participants on other medication classes (M = 12.02,
SD = 3.93; t (237) = -1.19, p = .23). There was, however, a significant difference in
MoCA scores between participants on metformin (M = 20.26, SD = 4.19) compared
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to participants on other medication classes (M = 18.67, SD = 5.05; t (229) = -2.31,
p = .02), suggesting participants taking metformin performed significantly better
on this measure compared to participants taking other anti-diabetic medications.
Post-hoc analyses
Cognitive diagnosis. Sample participants were diagnosed with a wide
variety of dementia diagnoses. These diagnoses include no cognitive impairment,
mild cognitive impairment (MCI), Alzheimer’s disease, vascular dementia, Lewy
body dementia, frontotemporal dementia, mixed dementia, cognitive disorder not
otherwise specified, and unspecified cognitive disorder. Due to low participant
frequencies in the diagnostic categories of vascular dementia, Lewy body dementia,
frontotemporal dementia, mixed dementia, cognitive disorder not otherwise
specified, and unspecified cognitive disorder, a category termed “dementia other”
was created to capture these diagnoses to allow for further analyses. Participants
also were diagnosed with a mood disorder diagnosis if mood difficulties were
detected throughout the testing process. The control group had 24 participants
within normal limits (WNL) (10%), 21 mood disorder (8.8%), 26 MCI (10.8%), 90
Alzheimer’s disease (37.5%), and 79 dementia other (32.9%). For the Type 2
diabetes group, 13 participants were within normal limits (WNL) (5.4%), 30 mood
disorder (12.6%), 46 MCI (19.2%), 69 Alzheimer’s disease (28.9%), and 74
dementia other (31.0%). Furthermore, 7 participants in this group’s testing results
were deemed inconclusive (2.9%) and a diagnosis was not provided.
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Figure 2. Frequency of patient diagnosis in control and Type 2 diabetes group

To determine whether or not there were statistically significant differences
between the Type 2 diabetes and control group in cognitive diagnosis, a chi square
test for independence was conducted. Results indicated a significant association
between group and cognitive diagnosis, c2 (5, n = 479) = 20.35, p = < .01, phi = .2.
Differences in test scores. To explore the impact of group on cognitive
performance on specific subtests within the BNE, independent- samples t-tests
were conducted. All comparisons were insignificant, as displayed in Table 2, with
the exception of performance on the Clock Drawing Test. Specifically, participants
in the Type 2 diabetes group (M = 7.37, SD = 2.63) performed significantly better
on the Clock Drawing Test than participants in the control group (M = 6.74, SD =
2.93; t (465) = -2.45, p = .02).
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Table 2. Results of t tests and descriptive statistics of test scores by group

Brief Exit
COWAT
Phonemic

Control Group
Scores
M
SD
8.38 4.37
8.48 2.97
2.93

Type 2 Diabetes Scores t-test p-value
M
8.25
8.36

SD
4.09
3.06

.32
.43

.75
.67

6.92

3.00

-1.06

.29

COWAT
Semantic

6.62

MackSF4

11.55 2.70

11.55

2.91

.01

1.00

Trails A

7.15

3.62

7.15

3.58

-.03

.98

Trails B

4.99

4.23

5.65

4.11

-1.66

.10

Clock
Drawing Test

6.74

2.93

7.37

2.63

-2.45

.02*

Supraspan
Best
Supraspan
Delay

6.57

1.88

6.65

1.77

-.46

.64

2.90

2.90

3.34

2.67

-1.65

.10

Discussion
Previous research indicated that individuals diagnosed with Type 2 diabetes
displayed accelerated levels of cognitive decline compared to individuals without
the disease across various cognitive domains (Awad, Gagnon, & Messier, 2004;
McCrimmon, Ryan, & Frier, 2012; Yeung & Fischer, 2009). Although this area has
been heavily studied, less research exists that investigates differences in cognitive
decline across varying levels of diabetes self-management as indicated by A1C
values. Secondly, a recent area of research exploring the relationship between the
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medication metformin for the treatment of Type 2 diabetes and its impact on
cognitive decline has yielded mixed results, with some studies demonstrating a
neuroprotective effect (Asadbegi, Yaghmaei, Salehi, Ebrahim-Habibi, & Komaki,
2016; Chung et al., 2014) and others demonstrating an increased risk of the
development of various neurodegenerative diseases (Chen et al., 2008; Imfeld,
Bodmer, Jick, & Meier, 2012; Yung-Cheng et al., 2014).
With a goal of a making a unique contribution to the aforementioned lines
of research, the present study investigated the role of Type 2 diabetes selfmanagement (as measured by A1C values) on levels of domain-specific cognitive
decline in older adults. A second aim of the present study was to determine whether
or not older adults taking the medication metformin to manage Type 2 diabetes
experienced differences in cognitive decline compared to those taking other
medications. Based on the review of literature in these areas, it was hypothesized
participants with higher A1C values would have significantly worse BNE scores
(i.e., more domains within the “borderline” or “impaired” range) as compared to
participants with A1C values within the normal range. The second hypothesis of
this study was exploratory and posited that the medication metformin would impact
cognitive performance as measured by the BNE.
Results of the current study do not support the first hypothesis that
participants with higher A1C values would be associated with lower BNE scores.
Specifically, this relationship was investigated using a Pearson product-moment
correlation coefficient and all correlations were found to be statistically
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insignificant. This lack of relationship may be explained in part by a significant
limitation of the current study regarding a lack of accurate dates of A1C measures
in patient medical records. Specifically, throughout data compilation, it was
determined there may have been delays in entering A1C values in patient medical
charts; therefore, the date of cognitive testing data and A1C values could not be
accurately matched with confidence. Furthermore, patient A1C values often did not
coincide with BNE testing dates, further adding to difficulty in matching A1C dates
with cognitive data. At the very least, this limitation added variance to the analysis
that may prevented a true effect from emerging.
The primary hypothesis of the present study was investigated further by
examining differences in BNE domain scores between the Type 2 diabetes and
control group. MANOVA results revealed a statistically significant difference
between the Type 2 diabetes and control group on BNE domain scores, specifically
regarding the visuospatial domain. An inspection of mean scores indicated that the
Type 2 diabetes group obtained slightly lower visuospatial scores. This finding is
rather unique from the reviewed literature as previous studies suggest domain
deficits to primarily occur in the executive functioning and motor processing speed
domains (Yeung, Fischer and Roger, 2009; Palta, Schneider, Biessels, Touradji &
Hill-Briggs, 2014). Although unique, this finding should be interpreted with
caution and the effect size of this finding was small and is overall incongruent with
the previous investigations of domain-specific cognitive deficits in Type 2 diabetes
samples.
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In addressing the exploratory hypothesis of the present study that the
medication metformin would impact cognitive performance as measured by the
BNE, BNE cognitive domain scores were compared for participants taking
metformin with participants taking all other classes of anti-diabetic medications. A
significant difference in the learning and memory domain scores was detected,
which suggests individuals who were taking metformin performed slightly better
on memory and learning measures. This finding is in line with an important study
conducted by Herath, Cherbuin, Eramudugolla, and Anstey (2016) that found
participants who took metformin demonstrated better cognitive performance in the
various areas of learning and memory.
The most important findings of this study emerged with regard to MoCA
score comparisons between the metformin and other medication group. It was
found participants on metformin performed significantly better on the MoCA than
participants on other anti-diabetic medications. This finding is important as the
MoCA is a well-established multi-domain measure of cognitive functioning.
Furthermore, this finding is rather unique as the reviewed literature did not indicate
previous studies utilizing the MoCA to explore cognitive decline in diabetic
participants.
Various analyses were conducted outside of the two primary hypotheses of
the present study. The aim of these post- hoc analyses were 1) to explore
differences in cognitive diagnosis amongst the Type 2 diabetes and control group
and 2) to explore potential differences in BNE subtests between the two groups.

47
Statistically significant differences were found in the cognitive diagnoses between
the Type 2 diabetes and control group. By exploring these differences closer,
within the Type 2 diabetes group, there were less participants with normal
cognitive functioning, and more participants with mood disorder and Mild
Cognitive impairment. Furthermore, more participants diagnosed with Alzheimer’s
disease were present in the control group. Although the investigation of mood
disorders in the Type 2 diabetes group was not an aim of the present study, a wellestablished body of research exists that links depression to diabetes. Specifically,
the relationship between diabetes and depression appears to be bi-directional,
suggesting diabetes increases the risk of depression, while depression also increases
the risk of diabetes (Gonzalez, Peyrot, Collins, Mimiaga & Safren, 2008)
Furthermore, stress and anxiety have also been linked to diabetes (Lloyd, Smith &
Weinger, 2005; Smith, Bèland, Clyde, Gariépy, Pagé, Badawi et al., 2013). The
higher frequency of mood disorders in the Type 2 diabetes group of the present
study appears to be in line with these findings. This study did not examine the
specific frequencies of specific mood disorders within the Type 2 diabetes group,
which may be an interesting future investigation.
Limitations
There are several limitations of the current study, most of which are related
to the Electronic Medical Record (EMR) System that was the source of the medical
data. The EMR utilized negatively affected data collection and analysis in multiple
ways. First, data received from the information technology professionals (IT) was
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displayed in a format that made it difficult to organize and convert into a format
that could be used for data analysis. A significant amount of time was spent reorganizing and properly formatting the data into a research-friendly format to
prepare for statistical analyses. Secondly, the patient data obtained from the EMR
had many shortcomings, the worst of which was the lack of accuracy in the dates
assigned to various patient information including A1C value measurements,
medication prescriptions, and the dates diagnoses were made. After discussion with
multiple medical professionals at the ECFMDC, it was determined that there was
often a significant delay in entry of medical information into patients’ charts after
changes and updates have been made, thus rendering the dates associated with this
information rather inaccurate. Being able to accurately link dates of medical data in
patients’ charts with the ECFMDC cognitive testing data was important for being
able to draw conclusions about patterns of cognitive decline related to both A1C
and anti-diabetic medications. As mentioned previously, it is likely the lack of
correlational findings between A1C and BNE cognitive domain scores are
accounted for by errors in BNE date and A1C date.
Potential inaccuracy of EMR date information significantly impacted the
statistical analyses related to anti-diabetic medications and cognition. Similar to the
previously discussed difficulties with linking A1C values and testing data, the same
challenges were present in linking medication dates with cognitive testing data.
Specifically, information obtained related to patient medication history lacked
crucial elements including information about compliance, when a medication was
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discontinued or added, and whether or not the medication documented was the first
instance the patient took the medication. Likewise, potentially important patient
medication information regarding the medications a patient may have took prior to
becoming a patient of Health First or at the ECFMDC were not present. Despite
request for multiple draws of data from the EMR system to address these
shortcomings, information to correct these limitations could not be obtained. To
account for these limitations, areas of this research project that relied less heavily
on dates were also explored.
Lastly, a notable limitation of the present study was the lack of racial and
ethnic diversity since the sample was predominately Caucasian (88.5%) and nonHispanic. This limitation restricts the ability to generalize findings of the present
study to other, more diverse, samples.
Future Directions
Research exploring the role of anti-diabetic medications on Type 2 diabetes
will generate the clearest results when conducted within a medical environment
where the variables of interest are collected and documented in a structured and
experimenter-friendly IT environment. These characteristics allow the researcher to
maintain control of many factors that influence the outcomes of this line of research
including the collection of crucial information related to A1C values, medication
compliance, and medication history. If it is necessary to utilize archival data, it
should be ensured data is being extracted from a database that allows for the
collecting of comprehensive and accurate data. Furthermore, based on the findings
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of the present study, an interesting area for future research may be exploring the
use of the MoCA for detecting cognitive decline in the diabetic population.
Conclusions
Although further research is necessary to gain an understanding of the role
of A1C values and metformin use on domain-specific cognitive decline, the
investigations of the current study revealed interesting findings. In contrast to the
reviewed literature on domain-specific cognitive decline in a diabetic sample, this
study demonstrated more homogeneity between the control and Type 2 diabetes
group than expected. Specifically, few differences in cognitive domain scores were
found across groups. This possibly suggests that other important factors may be
influencing patterns of cognitive decline more heavily, including the specific
cognitive diagnosis and age. The strongest findings of this study were related to
metformin use. These suggest a neuroprotective effect of metformin, specifically
with regard to learning and memory skills. Moreover, this study also demonstrated
significant differences in cognition on the MoCA, a well-established multi-domain
measure of cognition, suggesting better performance for participants taking
metformin compared other anti-diabetic medications. Overall, these findings make
an important contribution to the mixed literature on the impact of metformin on
cognitive functioning in diabetic patients.
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